Stock CANF CAN-FITE BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Can-Fite BioPharma Ltd.

Equities

CANF

IL0010944739

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 08:49:49 2024-05-12 am EDT 		5-day change 1st Jan Change
2.7 ILa 0.00% Intraday chart for Can-Fite BioPharma Ltd. -3.57% +3.85%
May. 12 Transcript : Can-Fite BioPharma Ltd. - Special Call
May. 09 Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study CI

Evolution of the average Target Price on Can-Fite BioPharma Ltd.

Price target over the last 5 years

History of analyst recommendation changes

d479df9b7d52f17a2751b32877467fbc.__Ff7UPD56DSw6Czim4DLYqxTIiPX3jzQajy81pfdnk.kpgYrByJpdi5hMTEpzYwRv_BDbnkDSCqKvmUrBlrABGRthjAFfO-wqKn1w~2a3cb130a4a8254b4388d39b3378055a

Analyst Recommendations on Can-Fite BioPharma Ltd.

HC Wainwright Adjusts Can-Fite Biopharma Price Target to $18 From $34, Maintains Buy Rating MT
CAN FITE BIOPHARMA : Aegis Capital Starts Can-Fite Biopharma at Buy with $5 Price Target MT
DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.027
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Can-Fite BioPharma Ltd.

HC Wainwright
Aegis Capital

Ratings for Can-Fite BioPharma Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CANF Stock
  4. Consensus Can-Fite BioPharma Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW